An Open-labeled Phase II Study to Evaluate the Efficacy and Safety of GXNPC-1 in Patients with Chronic Stroke
PHASE2CompletedINTERVENTIONAL
Enrollment
12
Participants
Timeline
Start Date
February 6, 2020
Primary Completion Date
August 15, 2023
Study Completion Date
September 3, 2024
Conditions
Chronic Stroke
Interventions
DRUG
GXNPC1
Autologous ADSCs
Trial Locations (1)
700
HualienTzu Chi Hospital, Hualien City
All Listed Sponsors
lead
Gwo Xi Stem Cell Applied Technology Co., Ltd.
INDUSTRY
NCT04088149 - An Open-labeled Phase II Study to Evaluate the Efficacy and Safety of GXNPC-1 in Patients with Chronic Stroke | Biotech Hunter | Biotech Hunter